DDInter1259 DDInter466
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Nalidixic acid {u} (Compound) upregulates {v} (Gene) PAK1
PAK1 {u} (Gene) is upregulated by {v} (Compound) Dactinomycin
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Dactinomycin
Nalidixic acid {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dactinomycin
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dactinomycin
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dactinomycin
Nalidixic acid {u} (Compound) upregulates {v} (Gene) PAK1
PAK1 {u} (Gene) is associated with {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Dactinomycin
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dactinomycin
Nalidixic acid {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} (Compound) binds {v} (Gene) SLC22A5
SLC22A5 {u} (Gene) is bound by {v} (Compound) Dactinomycin
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) binds {v} (Gene) SLC22A5
SLC22A5 {u} (Gene) is bound by {v} (Compound) Dactinomycin
Nalidixic acid {u} (Compound) resembles {v} (Compound) Rosoxacin
Rosoxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dactinomycin
Nalidixic acid (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Dactinomycin (Compound)
Nalidixic acid (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Dactinomycin (Compound)
Nalidixic acid (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Dactinomycin
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Dactinomycin
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Dactinomycin
Nalidixic acid (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is associated with kidney cancer (Disease) and kidney cancer (Disease) is treated by Dactinomycin (Compound)
Nalidixic acid (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Gatifloxacin (Compound) and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Dactinomycin
Nalidixic acid (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin (Compound) binds SLC22A5 (Gene) and SLC22A5 (Gene) is bound by Dactinomycin (Compound)
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) binds SLC22A5 (Gene) and SLC22A5 (Gene) is bound by Dactinomycin (Compound)
Nalidixic acid (Compound) resembles Rosoxacin (Compound) and Rosoxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Dactinomycin